Gaudium IVF and Women Health Limited

The Indian IVF market, currently valued at USD 1.32 billion, is projected to grow at a CAGR of 13% to USD 4.54 billion by 2034, with India's share of the global market expected to rise from 4.8% to 8.3%. Despite 27.5 million couples affected by infertility, only 3 lakh IVF cycles are performed annually, indicating a vast untapped market. The company notes a rising infertility rate (15-20% of 1.5 billion people) and decreasing fertility rates below replacement levels, creating a structural tailwind.

Gaudium IVF emphasizes its foundation in clinical excellence and patient trust, driven by its clinician-led DNA. The company reports a 58% success rate in the first IVF cycle, which is comparable to global standards (ASRM considers 40% good), and an 85% cumulative pregnancy rate over three attempts. This focus on outcomes and patient-first policy is highlighted as a key differentiator and a source of long-term trust, with the company having completed over 50,000 successful treatments since inception.

For Q4 FY26, Gaudium reported a revenue of INR 30.35 crore, a 12.74% YoY increase, and an EBITDA of INR 12.17 crore, representing a 39.56% YoY growth with a 40.10% margin. Full-year FY26 revenue stood at INR 104.35 crore, a 47.56% YoY increase from FY25's INR 70.72 crore. PAT for Q4 FY26 was INR 8.36 crore, up 29.46% YoY, and for the full year, it was INR 24.48 crore, demonstrating meaningful financial progress.

Following its IPO which raised approximately INR 165 crore, Gaudium is pursuing an aggressive expansion plan, aiming for 19 new IVF hubs, with 3 expected to be operational within the next couple of months (South Delhi, Nagpur, Gurgaon). The company also plans to add 9 spokes domestically and 3 international spokes (Paris, Nigeria, Sydney) this quarter, leveraging its asset-light hub-and-spoke model and strong medical tourism opportunity, with international patients currently contributing 25-30% of revenue.

Gaudium has become the first IVF chain in India to formally integrate AI-led embryology into routine clinical practices, partnering with IVF 2.0. The deployment of AI tools like SiD (for sperm selection) and ERICA (for embryo ranking) has already shown promising results, with an observed ~8% increase in the first-attempt success rate. This innovation is expected to enhance efficiency, reduce the number of attempts needed, and improve patient outcomes, reinforcing the company's clinical excellence.

Recognizing the high cost of IVF (base price INR 2 lakhs), Gaudium is implementing initiatives to improve affordability and accessibility. These include a Pan-India financing tie-up with HDFC Bank, credit schemes, and phased payment options allowing patients to pay over 5-6 months after initial egg retrieval and freezing. To manage trade receivables, which currently average ~150 days, the company has doubled initial payment requirements from INR 40,000 to INR 80,000 and introduced additional charges for delayed transfers, expecting a significant reduction in receivables.

The company attributes its consistent clinical outcomes across centers to a robust SOP-driven organizational structure, developed since 2014-15. This includes detailed protocols for all operations, compulsory in-house training and exit exams for all key clinical and embryology staff before deployment, ensuring that results across all centers remain within a 1% variation. This process-driven approach allows for scalable growth while maintaining high standards of clinical excellence, even as the founder's direct clinical involvement has reduced since 2019.